Literature DB >> 16086640

Short-term medical management of hydrocephalus.

Maria A Poca1, Juan Sahuquillo.   

Abstract

Hydrocephalus is an excess accumulation of cerebrospinal fluid in or around the brain that can be produced by a broad spectrum of disorders. It can develop at any age and its incidence is increasing, both in infants and adults. Although the standard treatment of hydrocephalus is cerebrospinal fluid shunting, there are certain circumstances in which medical treatment, alone or in combination with shunting, has been suggested as an alternative. This review aims to present and discuss the indications for pharmacological treatment in the medical management of hydrocephalus, and the drugs most frequently used. Carbonic anhydrase inhibitors, loop diuretic agents, osmotic agents and fibrinolytic therapy are discussed. The most suitable drug seems to be acetazolamide, alone or in combination with furosemide. At present, osmotic agents are no longer used in the treatment of hydrocephalus. Fibrinolytic therapy administered directly into the ventricular system may not avoid the need for shunt placement, but may help in the management of hydrocephalus by preventing or reducing the rate of catheter obstruction and accelerating clot resolution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086640     DOI: 10.1517/14656566.6.9.1525

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

1.  Severe neurologic impairment in mice with targeted disruption of the electrogenic sodium bicarbonate cotransporter NBCe2 (Slc4a5 gene).

Authors:  Liyo Kao; Lisa M Kurtz; Xuesi Shao; Marios C Papadopoulos; Li Liu; Dean Bok; Steven Nusinowitz; Bryan Chen; Salvatore L Stella; Mark Andre; Josh Weinreb; Serena S Luong; Natik Piri; Jacky M K Kwong; Debra Newman; Ira Kurtz
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

Review 2.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

3.  Liver X receptors regulate cerebrospinal fluid production.

Authors:  Y-B Dai; W-F Wu; B Huang; Y-F Miao; S Nadarshina; M Warner; J-Å Gustafsson
Journal:  Mol Psychiatry       Date:  2015-09-01       Impact factor: 15.992

4.  Nuclear factor κB activation impairs ependymal ciliogenesis and links neuroinflammation to hydrocephalus formation.

Authors:  Michael Lattke; Alexander Magnutzki; Paul Walther; Thomas Wirth; Bernd Baumann
Journal:  J Neurosci       Date:  2012-08-22       Impact factor: 6.167

5.  Subdural effusions with hydrocephalus after severe head injury: successful treatment with ventriculoperitoneal shunt placement: report of 3 adult cases.

Authors:  N Tzerakis; G Orphanides; E Antoniou; P J Sioutos; S Lafazanos; A Seretis
Journal:  Case Rep Med       Date:  2010-12-12

6.  Multiplicity of cerebrospinal fluid functions: New challenges in health and disease.

Authors:  Conrad E Johanson; John A Duncan; Petra M Klinge; Thomas Brinker; Edward G Stopa; Gerald D Silverberg
Journal:  Cerebrospinal Fluid Res       Date:  2008-05-14

7.  Gene expression and functional annotation of the human and mouse choroid plexus epithelium.

Authors:  Sarah F Janssen; Sophie J F van der Spek; Jacoline B Ten Brink; Anke H W Essing; Theo G M F Gorgels; Peter J van der Spek; Nomdo M Jansonius; Arthur A B Bergen
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 8.  Nonsurgical therapy for hydrocephalus: a comprehensive and critical review.

Authors:  Marc R Del Bigio; Domenico L Di Curzio
Journal:  Fluids Barriers CNS       Date:  2016-02-05

Review 9.  Hydrocephalus-Associated Hyponatremia: A Review.

Authors:  Chao Li; Iveth Mabry; Yasir R Khan; Michael Balsz; Rodolfo J Hanson; Javed Siddiqi
Journal:  Cureus       Date:  2022-02-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.